Cargando…
Randomised clinical trial: the clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China
BACKGROUND: There is a paucity of large‐scale studies evaluating the clinical benefit of the Gaviscon Double Action (DA) alginate‐antacid formulation for treating gastroesophageal reflux disease (GERD) symptoms. AIM: Randomised double‐blind placebo‐controlled parallel‐group study to evaluate efficac...
Autores principales: | Sun, J., Yang, C., Zhao, H., Zheng, P., Wilkinson, J., Ng, B., Yuan, Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042071/ https://www.ncbi.nlm.nih.gov/pubmed/26228097 http://dx.doi.org/10.1111/apt.13334 |
Ejemplares similares
-
Randomised clinical trial: the effectiveness of Gaviscon Advance vs non‐alginate antacid in suppression of acid pocket and post‐prandial reflux in obese individuals after late‐night supper
por: Deraman, Mohd Adli, et al.
Publicado: (2020) -
Gaviscon(® )vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial
por: Pouchain, Denis, et al.
Publicado: (2012) -
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence
por: Kruis, W., et al.
Publicado: (2017) -
Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020) -
Randomised clinical trial: the 5‐HT4 agonist revexepride in patients with gastro‐oesophageal reflux disease who have persistent symptoms despite PPI therapy
por: Shaheen, N. J., et al.
Publicado: (2015)